Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases

at the heart of it all

Muhammad Abdullah, Jessica M. Berthiaume, Monte Willis

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Inflammatory and immune signaling has been documented as a root cause of many cardiovascular pathologies. In this review, we explore the emerging role of tumor necrosis factor receptor-associated factor 6 (TRAF6)-nuclear factor kappa B (NF-κB) signaling axis in atherosclerosis, ischemic heart disease, pathologic cardiac hypertrophy or heart failure, myocarditis, and sepsis-induced cardiomyopathy. We discuss the current understanding of cardiac inflammation in heart disease, present the TRAF6 signaling axis in the heart, then summarize what is known about TRAF6 in pathophysiology of heart disease including proof-of-concept studies that identify the utility of blocking TRAF6 to attenuate cardiac dysfunction, which suggests that TRAF6 is a novel, druggable target in treating cardiovascular disease incurred by inflammatory processes.

Original languageEnglish (US)
Pages (from-to)48-61
Number of pages14
JournalTranslational Research
Volume195
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

TNF Receptor-Associated Factor 6
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins
NF-kappa B
Proteasome Endopeptidase Complex
Ubiquitin
Signal Transduction
Cardiovascular Diseases
Heart Diseases
Heart Failure
Therapeutics
Myocarditis
Cardiomegaly
Cardiomyopathies
Myocardial Ischemia
Sepsis
Atherosclerosis
Pathology
Inflammation

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Biochemistry, medical
  • Physiology (medical)

Cite this

Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases : at the heart of it all. / Abdullah, Muhammad; Berthiaume, Jessica M.; Willis, Monte.

In: Translational Research, Vol. 195, 01.05.2018, p. 48-61.

Research output: Contribution to journalReview article

@article{6643ef06738e45229de4aa1745fc8c6d,
title = "Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases: at the heart of it all",
abstract = "Inflammatory and immune signaling has been documented as a root cause of many cardiovascular pathologies. In this review, we explore the emerging role of tumor necrosis factor receptor-associated factor 6 (TRAF6)-nuclear factor kappa B (NF-κB) signaling axis in atherosclerosis, ischemic heart disease, pathologic cardiac hypertrophy or heart failure, myocarditis, and sepsis-induced cardiomyopathy. We discuss the current understanding of cardiac inflammation in heart disease, present the TRAF6 signaling axis in the heart, then summarize what is known about TRAF6 in pathophysiology of heart disease including proof-of-concept studies that identify the utility of blocking TRAF6 to attenuate cardiac dysfunction, which suggests that TRAF6 is a novel, druggable target in treating cardiovascular disease incurred by inflammatory processes.",
author = "Muhammad Abdullah and Berthiaume, {Jessica M.} and Monte Willis",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.trsl.2017.10.012",
language = "English (US)",
volume = "195",
pages = "48--61",
journal = "Translational Research",
issn = "1931-5244",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Tumor necrosis factor receptor-associated factor 6 as a nuclear factor kappa B-modulating therapeutic target in cardiovascular diseases

T2 - at the heart of it all

AU - Abdullah, Muhammad

AU - Berthiaume, Jessica M.

AU - Willis, Monte

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Inflammatory and immune signaling has been documented as a root cause of many cardiovascular pathologies. In this review, we explore the emerging role of tumor necrosis factor receptor-associated factor 6 (TRAF6)-nuclear factor kappa B (NF-κB) signaling axis in atherosclerosis, ischemic heart disease, pathologic cardiac hypertrophy or heart failure, myocarditis, and sepsis-induced cardiomyopathy. We discuss the current understanding of cardiac inflammation in heart disease, present the TRAF6 signaling axis in the heart, then summarize what is known about TRAF6 in pathophysiology of heart disease including proof-of-concept studies that identify the utility of blocking TRAF6 to attenuate cardiac dysfunction, which suggests that TRAF6 is a novel, druggable target in treating cardiovascular disease incurred by inflammatory processes.

AB - Inflammatory and immune signaling has been documented as a root cause of many cardiovascular pathologies. In this review, we explore the emerging role of tumor necrosis factor receptor-associated factor 6 (TRAF6)-nuclear factor kappa B (NF-κB) signaling axis in atherosclerosis, ischemic heart disease, pathologic cardiac hypertrophy or heart failure, myocarditis, and sepsis-induced cardiomyopathy. We discuss the current understanding of cardiac inflammation in heart disease, present the TRAF6 signaling axis in the heart, then summarize what is known about TRAF6 in pathophysiology of heart disease including proof-of-concept studies that identify the utility of blocking TRAF6 to attenuate cardiac dysfunction, which suggests that TRAF6 is a novel, druggable target in treating cardiovascular disease incurred by inflammatory processes.

UR - http://www.scopus.com/inward/record.url?scp=85036637543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036637543&partnerID=8YFLogxK

U2 - 10.1016/j.trsl.2017.10.012

DO - 10.1016/j.trsl.2017.10.012

M3 - Review article

VL - 195

SP - 48

EP - 61

JO - Translational Research

JF - Translational Research

SN - 1931-5244

ER -